

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO
DIRECCIÓN DE NUEVAS CREACIONES

2020
Bogotá, D.C.,

Abogada
Jimena Escobar
Apoderada

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO



No. 07-039651- -00004-0000

Fecha: 2010-09-23 14:41:56 Dep. 2020 DIR.NUEVASCR
Tra. 11 PATENTEIYII Eve: 379 FASENACIONALII
Act. 519 TRASLADOINFORME Folios: 1

ASUNTO	Radicación	07 39651
	Trámite	002
	Evento	001
	Actuación	430
	Oficio	112011
	Folios	012

Patente de Invención	☒	Patente de Modelo de Utilidad	☐
Vía Nacional	☐		
Vía PCT (fase nacional)	☒	Cap.I	☐
		Cap. II	☒
No. Sol. Internacional	PCT/US2005/040372		
Fecha de Presentación Internal.	07/11/05		

Como resultado del examen de fondo, realizado con fundamento en el artículo 45 de la Decisión 486 de la Comisión de la Comunidad Andina, se le comunica:

1. Documentos estudiados

- 1.1. Descripción: Folios 10 - 131
- 1.2. Reivindicaciones: Folios 186 – 209
- 1.3. Prioridad: Presentada en Estados Unidos, el 09.11.04, bajo el número 60/626785 y la 60/709648 de 19.08.08

2. Objeto de la invención

- Título de la solicitud: “Compuestos y composiciones como inhibidores de proteína quinasa”

Según las reivindicaciones 1-11 se refiere a compuestos de fórmula I y sus sales, hidratos, solvatos e isómeros farmacéuticamente aceptables. Dichos compuestos son inhibidores de proteína quinasa

El problema planteado en esta solicitud es la necesidad de más compuestos inhibidores de proteína quinasa.

Para solucionar este problema técnico la solicitud en estudio proporciona los compuestos de la presente solicitud

- Clasificación Internacional de Patentes A 61 K 31/4178

3. De la solicitud de Patente

3.1. Reivindicaciones (artículo 30 D 486)

- En las reivindicaciones 1-6, las numerosas variables, su voluminosa cantidad de significados complejos, sus permutaciones y combinaciones sin fin, hacen virtualmente imposible determinar el significado y el alcance real de la materia reivindicada. Por lo tanto, de la manera como se encuentra presentada, la materia reivindicada no es clara ni concisa, haciendo imposible efectuar una búsqueda significativa de la misma. Se le pide al solicitante restringir la materia a aquella que realmente se encuentra sustentada en la descripción y que realmente soluciona el problema técnico propuesto.

4. Excepciones a la patentabilidad (artículo 20 D 486)

El contenido de las reivindicaciones 9-10, que trata de “Un método para tratar...”, no es patentable, debido a que se relaciona con métodos terapéuticos aplicados a seres humanos o a animales.

5. Determinación del Estado de la Técnica

Considerando que la fecha de presentación de la primera solicitud de patente de la cual se reivindica prioridad es 09.11.04, se buscaron documentos del estado de la técnica relacionados, con fecha de publicación anterior a esta.

N°	Documento	Título	Fecha de Publicación
D1	WO 03051838	“Inhibidores de proteína quinasa”	26.06.03
D2	WO 0160814	“2-indolinonas pirrol sustituidas inhibidores de proteína quinasa”	23.08.01
D3	WO 0056710	“3-(anilinetileno) oxindoles como inhibidores de proteína tirosina quinasa y proteína serina/treonina quinasa”	28.09.00
D4	WO 9915500	“Derivados de oxindol sustituidos como inhibidores de proteína tirosina quinasa y proteína serina/treonina quinasa”	01.04.99
D5	WO 9948868	“Familias de compuestos heterocíclicos para la modulación de proteína tirosina quinasa”	30.09.99
D6	WO 0194312	“Derivados de indolinona como	13.12.01

		inhibidores de quinasa/fosfatasa"	
D7	WO 9961421	"Un inhibidor VLA-4 novedoso: oMEPUPA-V"	02.12.99
D8	WO 0008202	3-metilidenil-2-indolinona moduladores de proteína quinasa"	17.02.00

6. Análisis de patentabilidad (artículo 14 D486)

6.1. Novedad (artículo 16 D486)

- D1 en sus ejemplos 1-13 y reivindicaciones se relaciona con compuestos inhibidores de proteína quinasa
- D2 revela en sus ejemplos 9, 11, 14, 25, 43, 49, 54-62, 66-68, 75-79 y 95 compuestos inhibidores de proteína quinasa
- D3 publica en sus ejemplos 73-81 y 99-106 compuestos inhibidores de proteína quinasa
- D4 revela en sus ejemplos 16, 37, 40, 57 compuestos específicos inhibidores de proteína quinasa
- D5 en sus reivindicaciones 39 y 51, así como en las páginas 229-234 y tabla 9 compuestos inhibidores de proteína quinasa
- D6 en la tabla 9, revela compuestos específicos inhibidores de proteína quinasa
- D7 revela los compuestos 29-37 de la tabla 1 y los compuestos 47-53 de la tabla 2 inhibidores de proteína quinasa.
- D8 en su tabla 1 revela los compuestos 87, 101-103, 107-110, 144, 206, 207, 223 y 224 que son inhibidores de proteína quinasa.
- La reivindicación 7 se relaciona con compuestos que son inhibidores de proteína quinasa

Comparando elemento por elemento, D1-D8 ya enseñaban compuestos específicos que caen dentro del listado de compuestos de la reivindicación 7, afectando la novedad de la presente solicitud.

7. Conclusión:


Los requisitos de patentabilidad de la presente solicitud se encuentran afectados así:

Nº	Documento	Reivindicaciones Afectadas	Requisito que Afecta
D1	WO 03051838	7	Novedad
D2	WO 0160814	7	Novedad
D3	WO 0056710	7	Novedad
D4	WO 9915500	7	Novedad
D5	WO 9948868	7	Novedad
D6	WO 0194312	7	Novedad

D7	WO 9961421	7	Novedad
D8	WO 0008202	7	Novedad

En cumplimiento del artículo 45 de la Decisión 486 de la Comisión de la Comunidad Andina, se le indica que debe dar respuesta dentro del término de sesenta días contados a partir de la fecha de notificación de la presente comunicación. En caso de no dar respuesta al presente requerimiento, o si a pesar de la respuesta subsistieran los impedimentos para la concesión, se denegará la patente.

Notifíquese el presente oficio conforme a lo dispuesto en el numeral 5.2, literal e), del capítulo 5 del título primero de la Circular Única N° 10 de 2001.


Álix Carmenza Céspedes de Vergel
Directora de Nuevas Creaciones (c)

El anterior requerimiento fue notificado por fijación en lista, de fecha 24 SET. 2010

CONCEPTO TÉCNICO No. 3276	EXAMINADOR TÉCNICO Código No.202024
-------------------------------------	---

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
26 June 2003 (26.06.2003)

PCT

(10) International Publication Number
WO 03/051838 A2

(51) International Patent Classification⁷: **C07D 209/00**

Andrew Drive, Vernon Hills, IL 60061 (US). **XIA, Ping**;
1054 Lakehurst Drive, #303, Waukegan, IL 60085 (US).

(21) International Application Number: PCT/US02/39641

(22) International Filing Date:
12 December 2002 (12.12.2002)

(74) Agents: **STEELE, Gregory, W.** et al.; Dept 377/AP6D-2,
100 Abbott Park Road, Abbott Park, IL 60064-6050 (US).

(25) Filing Language: English

(81) Designated States (*national*): CA, JP, MX.

(26) Publication Language: English

(84) Designated States (*regional*): European patent (AT, BE,
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT,
LU, MC, NL, PT, SE, SK, TR).

(30) Priority Data:
10/022,290 13 December 2001 (13.12.2001) US

Published:

*without international search report and to be republished
upon receipt of that report*


(71) Applicant: **ABBOTT LABORATORIES** [US/US];
Dept. 377/AP6D-2, 100 Abbott Park Road, Abbott Park,
IL 60064-6050 (US).

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(72) Inventors: **LIN, Nan-Horng**; 432 W. Sycamore Street,
Vernon Hills, IL 60061 (US). **SHAM, Hing, L.**; 1666 N. St.



(54) Title: PROTEIN KINASE INHIBITORS



(I)

WO 03/051838 A2

(57) Abstract: Compounds having the formula (I) or therapeutically acceptable salts thereof, are protein kinase inhibitors. Preparation of the compounds, compositions containing the compounds, and treatment of diseases using the compounds are disclosed.

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
23 August 2001 (23.08.2001)

PCT

(10) International Publication Number
WO 01/60814 A2

(51) International Patent Classification⁷: C07D 403/00

(21) International Application Number: PCT/US01/04813

(22) International Filing Date: 15 February 2001 (15.02.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/182,710	15 February 2000 (15.02.2000)	US
60/216,422	6 July 2000 (06.07.2000)	US
60/243,532	27 October 2000 (27.10.2000)	US

(71) Applicant (*for all designated States except US*): SUGEN, INC. [US/US]; 230 East Grand Avenue, South San Francisco, CA 94080-4811 (US).

(71) Applicants and

(72) Inventors: TANG, Peng, Cho [US/US]; 827 Camino Ricardo, Morago, CA 94556 (US). MILLER, Todd [US/US]; 1713 N.E. Hollow Tree Lane, Bend, OR 97701 (US). LI, Xiaoyuan [US/US]; 2020 Victoria Court, Los Altos, CA 94024 (US). SUN, Li [CN/US]; 1151 Rickover Lane, Foster City, CA 94404 (US). WEI, Chung, Chen [US/US]; 39 Commons Lane, Foster City, CA 94404 (US). SHIRAZIAN, Shahrzad [IR/US]; 1 Constitution Drive, Corte Madera, CA 94925 (US). LIANG, Congxin [US/US]; 729 W. Remington Drive, Sunnyvale, CA 94087

(US). VOJKOVSKY, Tomas [CZ/US]; 333 Catalpa #6, San Mateo, CA 94080 (US). NEMATALLA, Asaad, S. [US/US]; 4492 Sweet Shrub Court, Concord, CA 94521 (US).

(74) Agent: BURROUS, Beth, A.; Foley and Lardner, 3000 K Street, NW, Suite 500, Washington, DC 20007 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/60814 A2

(54) Title: PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS

(57) Abstract: The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.



219

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07D 209/40, 487/06, 513/06, 405/04, 401/04, 405/14, 409/04, A61K 31/40, 31/415, 31/425, 31/41, 31/47, A61P 35/00 // (C07D 487/06, 209:00, 235:00) (C07D 487/06, 209:00, 253:00) (C07D 513/06, 209:00, 277:00) (C07D 487/06, 209:00, 221:00)	A1	(11) International Publication Number: WO 00/56710 (43) International Publication Date: 28 September 2000 (28.09.00)
(21) International Application Number: PCT/US00/05057 (22) International Filing Date: 28 February 2000 (28.02.00) (30) Priority Data: 9904933.0 4 March 1999 (04.03.99) GB (71) Applicant (for all designated States except US): GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): GLENNON, Kimberley, Caroline [US/US]; Glaxo Wellcome Inc., Five Moore Drive, P.O. Box 13398, Research Triangle Park, NC 27709 (US). KUYPER, Lee, Frederick [US/US]; Glaxo Wellcome Inc., Five Moore Drive, P.O. Box 13398, Research Triangle Park, NC 27709 (US). LACKEY, Karen, Elizabeth [US/US]; Glaxo Wellcome Inc., Five Moore Drive, P.O. Box 13398, Research Triangle Park, NC 27709 (US). MCNUTT, Robert,		Walton, Jr. [US/US]; 301 Dunhill Drive, Durham, NC 27713 (US). (74) Agents: LEVY, David, J.; Glaxo Wellcome Inc., Five Moore Drive, P.O. Box 13398, Research Triangle Park, NC 27709-3398 (US) et al. (81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.
(54) Title: 3-(ANILINOMETHYLENE) OXINDOLES AS PROTEIN TYROSINE KINASE AND PROTEIN SERINE/THREONINE KINASE INHIBITORS (I) (57) Abstract Compounds of formula (I) wherein R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, A, D, X, Y and Z have the meaning as defined in the claims exhibit protein tyrosine kinase and protein serin/threonine kinase inhibitory activity.		



220

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁶:

C07D 209/40, A61K 31/40, C07D 209/34,
401/06, 403/04, 413/04, 403/12, 405/12,
401/12, 498/04, 513/04, 487/04, 471/04,
491/04 // (C07D 498/04, 263:00, 209:00)
(C07D 487/04, 231:00, 209:00) (C07D
487/04, 249:00, 209:00) (C07D 487/04,
209:00, 209:00) (C07D 471/04, 221:00,
221:00) (C07D 491/04, 317:00, 209:00)

A1

(11) International Publication Number:

WO 99/15500

(43) International Publication Date:

1 April 1999 (01.04.99)

(21) International Application Number: PCT/EP98/05559

(22) International Filing Date: 3 September 1998 (03.09.98)

(30) Priority Data:

9718913.8

5 September 1997 (05.09.97)

GB

(71) Applicant (for all designated States except US): GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): DAVIS, Stephen, Thomas [US/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US). DICKERSON, Scott, Howard [US/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US). FRYE, Stephen, Vernon [US/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US). HARRIS, Philip, Anthony [GB/US]; Glaxo Wellcome Inc., Five Moore Drive,

Research Triangle Park, NC 27709 (US). HUNTER, Robert, Neil, III [US/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US). KUYPER, Lee, Frederick [US/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US). LACKEY, Karey, Elizabeth [US/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US). LUZZIO, Michael, Joseph [US/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US). VEAL, James, Marvin [US/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US). WALKER, Duncan, Herrick [US/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US).

(74) Agent: REED, Michael, A.; Glaxo Wellcome plc, Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published


With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: SUBSTITUTED OXINDOLE DERIVATIVES AS PROTEIN TYROSINE KINASE AND AS PROTEIN SERINE/THREONINE KINASE INHIBITORS

(57) Abstract

Compounds of formula (I): wherein X is N, CH, CCF₃, or C(C₁₋₁₂ aliphatic); R⁴ is sulfonic acid, C₁₋₁₂ aliphatic-sulfonyl, sulfonyl-C₁₋₁₂ aliphatic, C₁₋₁₂ aliphatic-sulfonyl-C₁₋₆ aliphatic, C₁₋₆ aliphatic-amino, R⁷-sulfonyl, R⁷-sulfonyl-C₁₋₁₂ aliphatic, R⁷-aminosulfonyl, R⁷-aminosulfonyl-C₁₋₁₂ aliphatic, R⁷-sulfonylamino, R⁷-sulfonylamino-C₁₋₁₂ aliphatic, aminosulfonylamino, di-C₁₋₁₂ aliphatic amino, di-C₁₋₁₂ aliphatic aminocarbonyl, di-C₁₋₁₂ aliphatic aminosulfonyl, di-C₁₋₁₂ aliphatic amino, di-C₁₋₁₂ aliphatic aminocarbonyl, di-C₁₋₁₂ aliphatic aminosulfonyl-C₁₋₁₂ aliphatic, (R⁸)₁₋₃-Arylamino, (R⁸)₁₋₃-Arylsulfonyl, (R⁸)₁₋₃-Aryl-aminosulfonyl, (R⁸)₁₋₃-Aryl-sulfonylamino, Het-amino, Het-sulfonyl, Het-aminosulfonyl, aminoiminoamino, or aminoiminoaminosulfonyl, R⁵ is hydrogen; and further wherein R⁴ and R⁵ are optionally joined to form a fused ring, pharmaceutical formulations comprising them and their use in therapy, especially in the treatment of diseases mediated by CDK2 activity, such as alopecia induced by cancer chemotherapy or radiotherapy.



(I)



721

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 209/34, 403/06, 409/06, A61K 31/40, 31/415		A2	(11) International Publication Number: WO 99/48868
		(43) International Publication Date: 30 September 1999 (30.09.99)	


(21) International Application Number: PCT/US99/06468		ter [DE/US]; 334 Collingwood Street, San Francisco, CA 94114 (US). HUBBARD, Steven, R. [US/US]; 5465 Sylvan Avenue, Riverdale, NY 10471 (US). LANGECKER, Peter [US/US]; 17610 Via Sereno, Monte Sereno, CA 95030 (US). LIANG, Congxin [CN/US]; 726 W. Remington Drive, Sunnyvale, CA 94087 (US). MCMAHON, Gerald [US/US]; 1800 Schultz Road, Kenwood, CA 95452 (US). MOHAMMADI, Moosa [IR/US]; 564 First Avenue #12F, New York, NY 10016 (US). SCHLESSINGER, Joseph [IL/US]; 37 Washington Square West, New York, NY 10011 (US). SHAWVER, Laura, K. [US/US]; 216 Cotter Street, San Francisco, CA 94112 (US). SUN, Li [CN/US]; 64 Rock-harbor Lane, Foster City, CA 94404 (US). TANG, Peng, C. [US/US]; 827 Camino Ricardo, Moraga, CA 94556 (US). ULLRICH, Axel [DE/DE]; Turkenstrasse 104, D-80799 München (DE).
(22) International Filing Date: 26 March 1999 (26.03.99)		
(30) Priority Data:		
60/079,713	26 March 1998 (26.03.98) US	
60/080,422	2 April 1998 (02.04.98) US	
60/081,792	15 April 1998 (15.04.98) US	(74) Agents: WARBURG, Richard, J. et al.; Lyon & Lyon LLP, Suite 4700, 633 West Fifth Street, Los Angeles, CA 90071-2066 (US).
60/082,056	16 April 1998 (16.04.98) US	
60/089,397	15 June 1998 (15.06.98) US	
60/089,521	16 June 1998 (16.06.98) US	
60/098,783	1 September 1998 (01.09.98) US	
(71) Applicants (for all designated States except US): SUGEN, INC. [US/US]; 230 East Grand Avenue, South San Francisco, CA 94080 (US). NEW YORK UNIVERSITY [US/US]; 550 First Avenue, New York, NY 10016 (US). MAX-PLANCK INSTITUT FÜR BIOCHEMIE [DE/DE]; Am Klopferspitz 18A, D-82152 Martinsried (DE).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(72) Inventors; and		
(75) Inventors/Applicants (for US only): FONG, Annie [US/US]; 811 Shetland Place, Sunnyvale, CA 94087 (US). HANNAH, Alison [US/US]; 3449 Brittan Avenue, San Carlos, CA 94070 (US). HARRIS, David, G. [US/US]; 417 Roosevelt Way, San Francisco, CA 94114 (US). HIRTH, Pe-		

Published
Without international search report and to be republished upon receipt of that report.

(54) Title: HETEROCYCLIC FAMILIES OF COMPOUNDS FOR THE MODULATION OF TYROSINE PROTEIN KINASE

(57) Abstract

The invention relates to certain indolinone-based and pyrazolylamide-based compounds, their method of synthesis, and combinatorial libraries consisting of the compounds. The invention also relates to methods of modulating the function of protein kinases using these compounds and methods of treating diseases by modulating the function of protein kinases and related signal transduction pathways.



(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
13 December 2001 (13.12.2001)

PCT

(10) International Publication Number
WO 01/94312 A2

(51) International Patent Classification⁷: **C07D 209/34**,
A61K 31/404, A61P 43/00, C07D 401/14, 403/14

(74) Agents: **BURROUS, Beth, A.** et al.; Foley & Lardner,
Washington Harbour, Suite 500, 3000 K Street N.W., Wash-
ington, DC 20007-5109 (US).

(21) International Application Number: **PCT/US01/17961**

(22) International Filing Date: **4 June 2001 (04.06.2001)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
60/209,162 **2 June 2000 (02.06.2000)** **US**

(71) Applicant (for all designated States except US): **SUGEN, INC.** [US/US]; 230 East Grand Avenue, South San Francisco, CA 94080-4811 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GI, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventors; and

(75) Inventors/Applicants (for US only): **TANG, Peng, Cho** [US/US]; 827 Camino Ricardo, Moraga, CA 94556 (US). **HARRIS, G., Davis** [US/US]; 417 Roosevelt Way, San Francisco, CA 94114 (US). **LI, Xiaoyuan** [CN/US]; 2437 Verwood Drive, San Jose, CA 95130 (US).



WO 01/94312 A2

(54) Title: **INDOLINONE DERIVATIVES AS PROTEIN KINASE/PHOSPHATASE INHIBITORS**

(57) Abstract: The present invention relates to certain 2-indolinone compounds which modulate the activity of protein kinases ("PKs") and phosphatases. The compounds of this invention are therefore useful in treating disorders related to abnormal PK activity. Pharmaceutical compositions comprising these compounds, methods of treating diseases utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



23

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 207/16, A61K 31/40		A1	(11) International Publication Number: WO 99/61421
			(43) International Publication Date: 2 December 1999 (02.12.99)
(21) International Application Number: PCT/US99/11924 (22) International Filing Date: 28 May 1999 (28.05.99) (30) Priority Data: 60/087,064 28 May 1998 (28.05.98) US (71) Applicant (for all designated States except US): BIOGEN, INC. [US/US]; 14 Cambridge Center, Cambridge, MA 02142 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): LEE, Wen-Cherng [-/US]; 192 Spring Street, Lexington, MA 02173 (US). GILL, Alan [US/US]; 6 Heather Drive, Reading, MA 01867-3959 (US). (74) Agent: FLYNN, Kerry; Biogen, Inc., 14 Cambridge Center, Cambridge, MA 02142 (US).			(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: A NOVEL VLA-4 INHIBITOR: oMePUPA-V (57) Abstract OMePUPA-V, (R)-N-[[4-[[[(2-methylphenylamino)carbonyl]amino]phenyl]acetyl]-L-prolyl-3-methyl]-β-Alanine, a cell adhesion inhibitor, pharmaceutical compositions, and methods of treatment of cell-adhesion mediated pathologies.			

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



224

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12Q		A2	(11) International Publication Number: WO 00/08202
			(43) International Publication Date: 17 February 2000 (17.02.00)
(21) International Application Number: PCT/US99/17845		(74) Agents: ROSE, Bernard, F. et al.; Lyon & Lyon LLP, Suite 4700, 633 West Fifth Street, Los Angeles, CA 90071-2066 (US).	
(22) International Filing Date: 4 August 1999 (04.08.99)			
(30) Priority Data: 09/129,256 4 August 1998 (04.08.98) US 60/095,470 5 August 1998 (05.08.98) US 60/102,178 28 September 1998 (28.09.98) US 60/116,107 15 January 1999 (15.01.99) US		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(71) Applicant (for all designated States except US): SUGEN, INC. [US/US]; 230 East Grand Avenue, South San Francisco, CA 94080-4811 (US).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): TANG, Peng, Cho [-/US]; 827 Camino Ricardo, Moraga, CA 94556 (US). SUN, Li [-/US]; 64 Rockharbor Lane, Foster City, CA 94556 (US). MILLER, Todd, Anthony [-/US]; 4928 Colusa Street, Union City, CA 94587 (US). LIANG, Congxin [-/US]; 729 West Remington Drive, Sunnyvale, CA 94087 (US). TRAN, Ngoc, My [-/US]; 550 Shannon Way, Spt. #6306, Redwood City, CA 94065 (US). NGUYEN, Anh, Thi [-/US]; 503 Becado Place, Fremont, CA 94539 (US). NEMATALLA, Asaad [-/US]; 1324 Bodega Place, Walnut Creek, CA 94596 (US).		Published Without international search report and to be republished upon receipt of that report.	
(54) Title: 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE			
(57) Abstract The present invention relates to novel 3-methylidenyl-2-indolinone compounds and physiologically acceptable salts and prodrugs thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.			